Pharma Globenewswire

CRISPR Therapies Clinical Trial Pipeline Appears Robust With 25+ Key Pharma Companies Actively Working in the Domain | DelveInsight

9 February 2026

DelveInsight’s, “CRISPR Therapies Pipeline Insight, 2025,” report provides comprehensive insights about 25+ companies and 30+ pipeline drugs in CRISPR Therapies pipeline landscape. It covers the CRISPR pipeline drug profiles, including clinical and nonclinical stage products. It also covers the CRISPR Pipeline therapeutics assessment by product type,

Uncategorised

Atrial Fibrillation Treatment Pipeline Shows Strong Momentum as 12+ Pharma Companies in the Race | DelveInsight

9 February 2026

DelveInsight’s, “Atrial Fibrillation Pipeline Insight, 2025” report provides comprehensive insights about 12+ companies and 15+ pipeline drugs in Atrial Fibrillation pipeline landscape. It covers the Atrial Fibrillation pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Atrial Fibrillation

Imviva Biotech Receives FDA Orphan Drug Designation

Clinical Trials

FDA Grants Orphan Drug Designation to CTD402, an Off‑the‑Shelf Anti‑CD7 CAR‑T Therapy, for Rare T‑Cell Leukemias and Lymphomas

6 February 2026

The Food and Drug Administration (FDA) has granted orphan drug designation to CTD402, an investigational allogeneic anti‑CD7 CAR‑T cell therapy from Imviva Biotech, for the treatment of patients with relapsed or refractory T‑cell acute lymphoblastic leukemia (T‑ALL) and lymphoblastic lymphoma (T‑LBL). This

Uncategorised

Basal Cell Neoplasms Clinical Trial Pipeline Appears Robust With 25+ Key Pharma Companies Actively Working in the Domain | DelveInsight

5 February 2026

DelveInsight’s “Basal Cell Neoplasms Pipeline Insight 2025” report provides comprehensive insights about 25+ companies and 30+ pipeline drugs in the Basal Cell Neoplasms pipeline landscape. It covers the Basal Cell Neoplasms Pipeline drug profiles, including clinical and nonclinical stage products. It also

Uncategorised

TGF Beta Inhibitors Treatment Pipeline Shows Strong Momentum as 10+ Pharma Companies in the Race | DelveInsight

5 February 2026

DelveInsight’s “TGF Beta Inhibitors Pipeline Insight 2025” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in the TGF Beta Inhibitors pipeline landscape. It covers the TGF Beta Inhibitors Pipeline drug profiles, including clinical and nonclinical stage products. It also

Uncategorised

Bipolar Disorder Clinical Trial Pipeline Expands as 20+ Companies Driving Innovation in the Therapeutics | DelveInsight

5 February 2026

DelveInsight’s “Bipolar Disorder Pipeline Insight 2025” report provides comprehensive insights about 20+ companies and 20+ pipeline drugs in the Bipolar Disorder pipeline landscape. It covers the Bipolar Disorder Pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Bipolar

Uncategorised

Advanced Liver Cancer Clinical Trial Pipeline Shows Potential with Active Contributions from 50+ Key Companies | DelveInsight

5 February 2026

DelveInsight’s, “Advanced Liver Cancer Pipeline Insight 2025” Report provides comprehensive insights about 50+ companies and 52+ pipeline drugs in Advanced liver cancer pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Advanced Liver Cancer therapeutics assessment by

Uncategorised

Peanut Allergy Clinical Trial Pipeline Accelerates as 12+ Pharma Companies Rigorously Develop Drugs for Market Entry | DelveInsight

5 February 2026

DelveInsight’s, “Peanut Allergy Pipeline Insight, 2025” report provides comprehensive insights about 12+ companies and 15+ pipeline drugs in Peanut Allergy pipeline landscape. It covers the Peanut Allergy pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Peanut Allergy

Clinical Trials

Shilpa Medicare’s Biologicals Unit Secures FDA Orphan Drug Designation for Investigational Monoclonal Antibody Targeting Rare Blood Cancers

5 February 2026

Shilpa Biologicals Private Limited, a wholly-owned subsidiary of Shilpa Medicare Limited, in collaboration with Switzerland-based mAbTree Biologics AG, announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to their investigational biologic product. The designation covers a

Latest

CRISPR Therapies Clinical Trial Pipeline Appears Robust With 25+ Key Pharma Companies Actively Working in the Domain | DelveInsight

Atrial Fibrillation Treatment Pipeline Shows Strong Momentum as 12+ Pharma Companies in the Race | DelveInsight

FDA Grants Orphan Drug Designation to CTD402, an Off‑the‑Shelf Anti‑CD7 CAR‑T Therapy, for Rare T‑Cell Leukemias and Lymphomas

Basal Cell Neoplasms Clinical Trial Pipeline Appears Robust With 25+ Key Pharma Companies Actively Working in the Domain | DelveInsight

TGF Beta Inhibitors Treatment Pipeline Shows Strong Momentum as 10+ Pharma Companies in the Race | DelveInsight

Bipolar Disorder Clinical Trial Pipeline Expands as 20+ Companies Driving Innovation in the Therapeutics | DelveInsight

Advanced Liver Cancer Clinical Trial Pipeline Shows Potential with Active Contributions from 50+ Key Companies | DelveInsight

Peanut Allergy Clinical Trial Pipeline Accelerates as 12+ Pharma Companies Rigorously Develop Drugs for Market Entry | DelveInsight

Shilpa Medicare’s Biologicals Unit Secures FDA Orphan Drug Designation for Investigational Monoclonal Antibody Targeting Rare Blood Cancers

Recent Posts

Banner

Newsletter

Authors